Business Context and Reporting Period
Company: Galectin Therapeutics Inc. (GALT)
Filing Type: Form 8-K (Current Report)
Report Date: May 15, 2026
Reporting Period: Three months ended March 31, 2026
Context: The filing announces the company's results of operations and financial condition for the first quarter of 2026 and provides a business update. The detailed financial data is contained in a press release (Exhibit 99.1) incorporated by reference.
Key Financial Metrics
The provided text serves as a cover report and does not contain specific numerical values for financial performance. The filing explicitly states that the detailed results are located in the attached press release (Exhibit 99.1). Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not disclose specific material changes, variances, or comparative data versus the prior period. Investors must refer to the incorporated press release (Exhibit 99.1) for a comparison of the three months ended March 31, 2026, against prior periods.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing includes standard disclaimers that statements regarding future financial performance are forward-looking and subject to risks and uncertainties. Actual results may differ significantly from management's expectations.
Risk Factors: The company directs investors to the "Risk Factors" section of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent SEC filings for a comprehensive list of risks.
Unusual Items: No unusual items or contingencies are detailed in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 15, 2026) for specific Q1 2026 revenue, net loss, and cash position figures.
- Verify the company's cash runway and liquidity status as detailed in the press release.
- Consult the Form 10-K for the year ended December 31, 2025 for updated risk factors referenced in this filing.
- Confirm any updates to clinical trial progress or business strategy mentioned in the business update portion of the press release.